cyrilzakka/clinical-trials huggingface dataset:
SmartQuit Program for Smoking Cessation

This trial investigates how well a smartphone-based smoking cessation program called SmartQuit works to help patients stop smoking. SmartQuit is an smartphone application-based smoking cessation program that includes a defined program consisting of interactive evidence-based exercises for dealing more effectively with urges to smoke, a place to track desired behaviors, personalized plans for quitting, and a certificate of completion once the recommended program components are completed. SmartQuit may help patients quit smoking, lower healthcare costs and reduce premature tobacco-related deaths.

OUTLINE:

Patients use the SmartQuit program to learn and practice skill modules as often as they wish over 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Smokes at least five cigarettes daily for at least past 12 months
* Wants to quit in the next 30 days
* Interested in learning skills to quit smoking
* Resides in United States (US)
* Has at least daily access to their own smartphone
* Knows how to login and download a smartphone application from their smartphone
* Willing and able to read in English
* Not participating in other smoking cessation interventions (including our other intervention studies)
* Must be an employee of a company who is participating in recruitment
* Willing to complete one follow-up survey
* Provide email, phone, and mailing address
Shock Wave Therapy Versus Mechanical Traction on Mechanical Low Back Pain

investigate the effect of shock wave therapy versus mechanical traction on mechanical low back pain.

Chronic low back pain (CLBP) is a common condition that causes tremendous health and socio-economic problems. CLBP is a widespread problem. About 70%-80% of adults in the general population are expected to suffer at least a low back pain episode at some time in their lives1. CLBP is the leading cause of absenteeism at work and creates restrictions on movements, lasting disabilities, and impaired quality of life. Non-specific low back pain is described as low back discomfort, which cannot be attributed to a distinct, known etiology "(e.g., infection, tumors, osteoporosis, fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome)" 2. Non-specific low back pain is a mechanical musculoskeletal pain that has a symptom that varies according to the physical activity nature 3.

The practice of sitting with a healthy posture and preventing a protracted-standing position can often prevent simple low back pain. However, many kinds of low back pain are addressed with therapies as numerous as the causes of low back pain. The most important treatments are therapeutic measures, such as bed rest, assistive aids, traction therapy, heat, electrical stimulation, and manual therapy are the first choice treatments4. If these methods fails, invasive therapy procedures like nerve roots blocks and epidural injections are employed, and operations are carried out when no reaction to other treatments has been seen or if the disease status is critical. New conservative therapies, including extracorporeal shock wave therapy (ESWT), have recently been embraced 5.

Eligibility Criteria:
Inclusion Criteria:

* Age between (20 and 35 years)
* all subjects suffered from mechanical low back pain

Exclusion Criteria:

* Rheumatoid arthritis or backbone pathologies, and past lumbar vertebrae surgery or cancer were reported
Comparison Between PEEK With Autogenous Bone Graft and PEEK With Xenograft in Maxillary Sinus Augmentation

Comparison Between PEEK With Autogenous Bone Graft and PEEK With Xenograft in Maxillary Sinus Augmentation

Comparison Between PEEK With Autogenous Bone Graft and PEEK With Xenograft in Maxillary Sinus Augmentation: clinical, radiographic and histomorphometric analysis .

Eligibility Criteria:
Inclusion Criteria:

* posterior edentulous ridge less than 4mm in bone height

Exclusion Criteria:

* insufficient oral hygiene and motivation
Closing the Gap Between Self-reported and Accelerometer-based Physical Activity

This study examines the effect of a video-based intensity level demonstration on self-reported physical activity in individuals aged between 40 and 75 years. Aim of the video demonstration is to achieve a better concordance of physical activity reports with accelerometer-based measurements.

This study examines whether the demonstration of different intensity levels of physical activity by video in the context of a tablet PC (personal computer)-based survey can achieve a higher degree of concordance between self-reported and accelerometer-measured physical activity compared to an assessment without video demonstration. The recruitment of the study participants in the age range between 40 and 75 years takes place in a shopping center in the city Greifswald in Germany.

Informed consent consists of: (i) activity recording over 7 days using an accelerometer, (ii) completion of standardized questionnaires, (iii) participation in a standardized measurement of weight and height as well as waist and hip circumference.

Participants are asked to wear an accelerometer during the day for a period of 7 days. Subsequently, a questionnaire about the frequency, duration and intensity of physical activity in the last 7 days will be answered in the DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung)- examination center. Prior to the physical activity assessment the study participants are randomly assigned to the study conditions "Video" or "No Video" (ratio 1:1). Optionally, participants may receive feedback on their physical activity measured by accelerometer upon completion of the study.

Eligibility Criteria:
Inclusion Criteria:

-

Exclusion Criteria:

* cognitive impairment
* inadequate language skills
Shoulder Prosthesis Telerehab Care Trial

The goal of this clinical trial is to compare the rehabilitation by use of a smartphone-app with the usual care of physical therapy in patients, 60 years and older, who underwent a primary shoulder arthroplasty.

The main questions it aims to answer are:

* is the outcome of rehabilitation with the app as good as the usual care?
* is the outcome for both types of shoulder arthroplasty similar?
* what is the usability of the app?.

Participants will

* have treatment according to the group they are allocated to
* fill in questionnaires at specific moments during the rehabilitation stage (0 - 3 months ) and at 1 year post-surgery


Eligibility Criteria:
Inclusion Criteria:

* 60 years and older
* primary total shoulder arthroplasty (anatomical and reverse)
* osteoarthritis, cuff tear arthropathy, pseudoparalysis
* return home after discharge from hospital
* no brace after surgery
* sufficient verbal and written comprehension
* hospitalization insurance

Exclusion Criteria:

* revision arthroplasty
* arthroplasty for fracture or tumor
* neurological disease (parkinson, stroke, ...)
* no access to smartphone, tablet or internet connectivity
Comparing G6PD Tests Using Capillary Blood Versus Venous Blood

In this study we propose to determine the correlation in glucose-6phosphate dehydrogenase enzyme activity in capillary blood obtained from a finger stick versus a venous blood specimen. As secondary endpoints we will seek to correlate phenotype as determined by quantitative and qualitative G6PD test, genotype as determined by PCR and DNA sequencing with flow cytometry. The secondary endpoints are critical for the design of G6PD diagnostic test evaluation studies.

In this study we propose to determine the correlation in glucose-6 phosphate dehydrogenase enzyme activity in capillary blood obtained from a finger stick versus a venous blood specimen. We will also compare results of different G6PD tests with known G6PD genetic profiles. The results of the study will inform design of future G6PD diagnostic development \& evaluations. This research will be conducted in MaeSot Thailand, where G6PD deficiency has a high prevalence. Study participants will be recruited into three groups of 50 volunteers per group: 50 G6PD-deficient individuals, 50 G6PD-normal individuals, and 50 G6PD-intermediate individuals. Following a written informed consent, participants will donate about 3 ml of venous blood and about 4 drops of capillary blood (fingerstick). There will be no direct benefit to research participants.

Eligibility Criteria:
Inclusion Criteria:

* Previous G6PD test at SMRU clinic
* Patient willing to participate and sign informed consent form
* Patient willing to allow donated sample to be used in future research
* Subjects 18 years of age or older

Exclusion Criteria:

* patients with severe malaria or other severe illness
* Patients who received a blood transfusion in the last 3 months
* Patients who received primaquine in the past 1 month (this is to ensure that previous characterization of phenotype in the healthy subject has not been influenced by a recent hemolytic reaction)
Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy

This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is not detected until heart failure has already occurred. Testing for cardiac biomarkers, such as troponin I and/or T and B-type natriuretic peptide (BNP), may be useful in detecting heart damage earlier than other tests currently performed (such as echocardiogram and electrocardiogram).

PRIMARY OBJECTIVES:

I. To determine if specific biomarkers (troponin I and B-type natriuretic peptide \[BNP\]) detect cardiotoxicity earlier than standard clinical means in patients receiving sunitinib malate (SU11248) or sorafenib chemotherapy.

SECONDARY OBJECTIVES:

I. To prospectively evaluate the incidence and severity of cardiac toxicity related to sunitinib or sorafenib during chemotherapy.

OUTLINE:

Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.

Eligibility Criteria:
Inclusion Criteria:

* Patient age 18-85 years
* Starting a new course of chemotherapy at MD Anderson Cancer Center that includes sunitinib or sorafenib
* Has a life expectancy of greater than 6 months

Exclusion Criteria:

* Unstable angina within the last 3 months
* Myocardial infarction within the last 3 months
* Left ventricular ejection fraction (LVEF) less than 40%
* Decompensated heart failure (HF) in the last 3 months
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients

AIR STUDY

TITLE: Anti-Ischemic effects of Abciximab(Reopro)

PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).

INTERVENTION: Heparin vs. heparin + abciximab during PCI

PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow.

PATIENT ASSESSMENT:

1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.
2. Measurement of blood flow in selected suitable patients
3. 10 minute questionnaire before discharge and on visit on day 28.


Eligibility Criteria:
Inclusion Criteria:

1. Have either:

   * clinical history of anginal symptoms or positive stress test or
   * in stent restenosis
2. Have an angiographic \>70% coronary artery stenosis that will be treated with coronary angioplasty or stenting procedure
3. For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase inhibitor or a stable statin dose
4. negative pregnancy test
5. are able to give informed consent

Exclusion Criteria:

1. Coronary intervention within four weeks prior to enrollment.
2. Treatment with abciximab antagonist within four weeks.
3. treatment with thrombolytic therapy within 48 hours
4. MI within 2 months.
5. recent infections
6. general anesthesia within 3 months.
7. renal failure
Tramadol-paracetamol Combination in Treatment of Patients Undergoing Spinal Surgery

Tramadol-paracetamol combination is studied in patients coming for elective spine surgery. The study drug is started at the day of surgery and continued maximum of five days. Before the surgery pain, use of pain medication, satisfaction for pain medication, adverse effects, resilience, depression and life satisfaction were asked. At the discharge and seven days after the surgery use of pain medication and adverse effects were asked. The patients were followed up to 28 days and one year after surgery.


Eligibility Criteria:
Inclusion Criteria:

* age 18-75 years,
* BMI 18-35 kg/m2,
* informed consent obtained,
* elective spine surgery

Exclusion Criteria:

* Age\<18 years or \>75 years
* Hypersensitivity to anti-inflammatory drugs, paracetamol, tramadol or their auxiliary substances
* Acute or recovered hemorrhage in gastrointestinal tract or peptic ulcer
* Hemorrhagic disease
* Monoamineoxidase use in past two weeks
* Epilepsy
* Tendency to seizure
* Anti-seizure drugs in use Liver or renal failure Reduction in lung function Alcohol, drug or opioid addiction on record Acute intoxication due to alcohol, analgesics, opioids or psychopharmacon Pregnancy or breastfeeding Investigators estimation
Respiratory Muscle Training and Intermittent Hypoxia: Additive Health Effects?

The prevalence of pre-hypertension and hypertension in the elderly is very high. Apart from medication, physical exercise training is a potential strategy to reduce blood pressure, however, the ability to perform exercise can be limited in the elderly. Hence, alternative non-pharmacological strategies to reduce blood pressure are necessary. Two interventions that have been shown to positively influence blood pressure are respiratory muscle training (RMT) and intermittent hypoxia (IH). Whether a combination of RMT and IH yields even better effects is currently unknown. Therefore, in this study, the effect of a single session of RMT with and without IH on blood pressure and associated cardiovascular parameters will be investigated in elderly subjects with pre-hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Age: 65-80 years
* Systolic blood pressure between 130-139 mmHg and diastolic blood pressure lower than 90 mmHg
* Non smoking
* Normal Body-Mass-Index (BMI): 18.5-24.9 kg·m-2
* Normal Lung Function
* Willing to adhere to the general study rules

Exclusion Criteria:

* Known or suspected non-compliance, drug or alcohol abuse
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
* Previous enrolment into the current study
* Enrolment of the investigator, his/her family members, employees and other dependent persons
* Intake of blood pressure medication
* Intake of medications affecting sleep or the performance or the respiratory, cardiovascular or neuromuscular system
* Acute or chronic illness other than prehypertension
Efficacy of an Electronic System to Support Clinical Decisions in Adults With Type 2 Diabetes Mellitus.

To assess the efficacy of an electronic system to support clinical decisions based on an evidence-based clinical practice guide for metabolic control of adults with Type 2 Diabetes Mellitus through Clinical and cluster-randomized controlled trial in a Colombian population.


Eligibility Criteria:
Inclusion Criteria:

* No prior exposure to the tool (through development and beta testing)
* Access to an organized diabetes pathway consistent with the Sanitas EPS (Entidad Promotora de Salud) diabetes mellitus 2 guideline.

Exclusion Criteria:

* Terminally ill
Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population

The purpose of this study is to evaluate the safety and efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine after the first and second treatment when used for facial augmentation in Asian population.


Eligibility Criteria:
Inclusion Criteria:

* Subjects intent to undergo facial filler treatment for either volume loss or contouring
* Subjects requiring treatment in two to four of pre-defined areas in the face (upper cheeks, nasolabial folds, temples, nose and chin)
* Require 3-5 ml of investigational products to achieve a clinically meaningful improvement in appearance
* Facial appearance as Han Chinese
* Non-pregnant, non-breast feeding female
* Signed informed consent

Exclusion Criteria:

* Previous facial surgery (e.g. rhinoplasty) or permanent implant in the area to be treated.
* History of chronic sinusitis or rhinitis (only applicable for subjects injected in the nose).
* Subjects who needs to use heavy glasses during the study (only applicable for subjects injected in the nose).
* Previous tissue augmenting therapy or contouring with permanent filler or fat injection in the facial area.
* Previous treatment with Hyaluronic acid (HA) fillers or Restylane Skinboosters in the facial area within 12 months before treatment.
* Previous treatment with non-HA fillers such as CaHA (Calcium Hydroxylapatite) or PLLA (Poly L-Lactic Acid) within 24 months before treatment.
* Previous revitalization with neurotoxin in the facial area within six (6) months before treatment.
* Previous tissue revitalization treatment with laser or light, mesotherapy, chemical peeling or dermabrasion in the facial area within six (6) months before treatment.
* Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may interfere with the outcome of the study).
Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer

The primary aim of this trial is to rigorously evaluate the comparative benefits and potential risks associated with Billroth II reconstruction with Braun anastomosis versus Billroth II reconstruction alone following distal gastrectomy with D2 lymphadenectomy in patients diagnosed with gastric cancer. This assessment focuses on delineating the therapeutic efficacy, safety profile, and overall clinical outcomes of these two surgical approaches in treating this condition.


Eligibility Criteria:
Inclusion criteria

To be enrolled, participants must be phase I-III patients with initial treatment of radical distal gastrectomy and satisfying the following inclusion criteria:

1. Histologically proven stage I-III gastric cancer, evaluated as radically resectable
2. No synchronous or metachronous cancers
3. Patients have signed informed consent forms
4. Age 18-80 years old
5. No malfunction of cardio-pulmonary, liver, and kidney, ECOG score 0-1
6. No emergency surgery needed

Exclusion criteria

Patients will be excluded according to the following criteria:

1. Pregnant or lactating women
2. Distant metastasis to the liver, lung, bone, supraclavicular lymph nodes, pelvic, or ovarian species and peritoneal dissemination
3. Ascites or cachexia
4. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension or diabetes
5. Participation in other clinical trials 4 weeks before the enrollment of this trial or still participating in other trials
6. Mental illness
7. Surgical history whose influence has not been eliminated
8. History of another gastric or esophageal malignancy, including stromal tumor, sarcoma, lymphoma, and carcinoid
9. Active infection with a fever of over 38°C
10. Poor compliance
11. Not suitable for this trial because of other clinical or laboratory conditions determined by the researchers
Neural Correlates of Driving and Cannabis

Driving is a set of complex tasks and requires use of multiple cognitive domains, including attention, planning, and memory. In laboratory studies, the main psychoactive component in cannabis, delta-9-tetrahydrocannabinol (THC), was shown to impair short-term memory, attention, reaction time, tracking, and coordination, resulting, for instance, in significantly more deviations from the lane and increased break latency. Surveys and epidemiological studies suggest that cannabis consumption is associated with increased risks of collision.

The current study aims to evaluate individual driving behavior and performance on various neurocognitive tests and their correlated neural networks while under the influence of cannabis and while sober. The investigators will use the STISIM driving simulator, which is fully MRI compatible, to study brain activation, while participants are performing various driving maneuvers.

The goals of the study are:

1. identify driving performance and patterns in brain activation associated with cannabis exposure and compare them to brain patterns of the same participants while sober;
2. compare participant's performance on cognitive tasks while under the influence of cannabis and sober;
3. look for correlations between concentration of cannabinoids in the participants' blood and their driving performance and performance on cognitive tasks;
4. correlate demographic variables and personal history (e.g. tolerance to drug) with performance and brain activation while driving under the influence of cannabis.


Eligibility Criteria:
Inclusion Criteria:

* valid driver's license
* have normal or corrected-to-normal vision
* have had prior experience consuming cannabis
* are currently not and have not been regular users in the past 5 years (regular use is defined as at least 1 time per week for at least 1 month)
* prescribed medical cannabis

Exclusion Criteria:

* not fluent in English
* do not meet MRI screening criteria
* use 50 mg/day of morphine equivalents
* history of neurological, neurodegenerative or psychiatric diseases
* any serious sensory or motor impairments
* pregnant women or women trying to get pregnant, or breastfeeding
* serious lung, liver, kidney, and heart problems, including angina, coronary artery disease, and arrhythmia, and Peripheral Vascular Disease
* personal or family history of mental disorders or alcohol or drug abuse or dependence
Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU

Intensive Care Unit (ICU) acquired pneumonia, including ventilator-associated pneumonia, is a frequently occurring health-care associated infection, which causes considerable morbidity, mortality and health care costs. Important pathogens causing ICU pneumonia are Staphylococcus aureus and Pseudomonas aeruginosa. The epidemiology of ICU pneumonia and patient-related and contextual factors is not fully described, but is urgently needed to support the development of effective interventions.


Eligibility Criteria:
Inclusion Criteria:

1. Participant is 18 years or older at the time of enrollment.
2. Participant is on mechanical ventilation at ICU admission, or is (expected to be) within 24 hours thereafter, based on investigator's judgment.
3. Expected stay in ICU is 48 hours or longer based on investigator's judgment.
4. SA colonization status is known within 72 hours after start of first episode of mechanical ventilation and according to the result, the patient qualifies for enrollment.
5. Written informed consent from subject / legally accepted representative within 72 hours after start of first episode of mechanical ventilation.

Exclusion Criteria:

1. Previous participation as a subject in the study cohort of this study.
2. Simultaneous participation of the subject in any preventive experimental study into anti-staphylococcus or anti-pseudomonas aeruginosa interventions.
3. Expected death (moribund status) within 48h, or ICU discharge of the participant within 24h, at the moment of informed consent.